Alligator 和 Aptevo 报告了 ALG.APV-527 用于实体瘤治疗的 1 期试验的积极中期数据。 Alligator and Aptevo report positive interim data in Phase 1 trial of ALG.APV-527 for solid tumor treatment.
Alligator Bioscience 和 Aptevo Therapeutics 宣布其 1 期试验剂量递增阶段的积极中期数据，该试验评估 ALG.APV-527 用于表达肿瘤抗原 5T4 的实体瘤治疗。 Alligator Bioscience and Aptevo Therapeutics announce positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for solid tumor treatments expressing tumor antigen 5T4. 该试验入组人数超过 50%，初步结果显示 ALG.APV-527 药物暴露和生物活性。 The trial is over 50% enrolled, with preliminary results showing ALG.APV-527 drug exposure and biological activity. 在经过大量预处理的患者中观察到临床活动的早期迹象，预计到 2024 年 2 月可获得剂量递增试验数据。 Early signs of clinical activity are observed in heavily pretreated patients, and dose-escalation trial data is expected by 2H 2024.